YGX
Live / Allowed — Published for opposition (as of 24 Feb 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Mar 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99105786
- Mark type
- Stylized text
- Filed
- 26 Mar 2025
- Published for opposition
- 24 Feb 2026
- Attorney of record
- Eryn Y. Truong
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of oncological, hematological, immunological, neurological, cardiovascular, metabolic, infectious, inflammatory, dermatological, gastrointestinal, hepatic, respiratory, renal, ophthalmic, and musculoskeletal diseases and disorders in humans; Veterinary pharmaceutical preparations for the treatment of oncological, hematological, immunological, neurological, cardiovascular, metabolic, infectious, inflammatory, dermatological, gastrointestinal, hepatic, respiratory, renal, ophthalmic, and musculoskeletal diseases and disorders in animals
- Class 042 — Scientific and technological services: Pharmaceutical research services; Pharmaceutical product evaluation; Research in the field of pharmaceuticals; Research relating to pharmaceuticals; Pharmaceutical research and development services; Research on the subject of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Research and development of new products for the pharmaceutical industry; Consultancy in the field of pharmaceutical research; Consultancy relating to pharmaceutical research and development; Laboratory research in the field of pharmaceuticals; Technical research in the field of pharmaceuticals; Research and development in the pharmaceutical and biotechnology fields; Providing scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical products development; Pharmaceutical drug development services; Development of pharmaceutical preparations and medicines; Consultancy in the field of biotechnology; Consultancy relating to biotechnology; Biotechnology testing; Biotechnology research; Research relating to biotechnology; Scientific research; Scientific testing services in the field of pharmaceuticals; Scientific research services; Scientific research consulting; Scientific laboratory services
- Class 044 — Medical, beauty and agricultural services: Medical services in the nature of pharmaceutical consultation; Pharmaceutical advice; Pharmaceutical advisory services; Provision of pharmaceutical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals
- Class 045 — Legal and security services: Intellectual property consultation; Intellectual property consultancy; Intellectual property licensing services; Management of intellectual property; Licensing of intellectual property; Licensing of intellectual property rights; Consultancy relating to intellectual property management; Intellectual property management services; Advisory services relating to intellectual property rights; Consultancy relating to the licensing of intellectual property; Intellectual property consultancy services for universities and research institutions
Owner
- YGIX Medicines Limited, Shankill, Dublin, IE
- YGIX Medicines Limited, Shankill, Dublin, IE
Prosecution history
- 24 Feb 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Feb 2026 — PUBLISHED FOR OPPOSITION
- 18 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 29 Jan 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 23 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 23 Jan 2026 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 04 Nov 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 04 Nov 2025 — FINAL REFUSAL E-MAILED
- 04 Nov 2025 — FINAL REFUSAL WRITTEN
- 31 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 31 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 31 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 26 Aug 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 26 Aug 2025 — NON-FINAL ACTION E-MAILED